US FDA · Final guidance
FDA finalises guidance on postapproval biosimilar manufacturing changes
Official source date: · Source checked
FDA has issued final questions-and-answers guidance on manufacturing changes to licensed biosimilar and interchangeable biosimilar products, replacing the July 2024 draft.
Who should review this?
Biosimilar manufacturers, quality units, CMC teams and regulatory affairs professionals.
What it means for pharmaceutical teams
The guidance addresses postapproval changes to licensed biosimilars and interchangeable biosimilars. Teams should review the final text against the proposed change and its supporting information rather than continue relying on the superseded draft.
Practical review checklist
PharmaEdges reading prompts for your own applicability review:
- Use the October 2026 final guidance when reviewing a proposed change.
- Check the product scope and relevant questions against the change-control assessment.
- Coordinate the supporting evidence and reporting approach with quality and regulatory teams.
Official source and verification
Read the US FDA source (opens in a new tab)
This article summarises the linked official material. The context and checklist are PharmaEdges explanatory commentary, not additional regulatory requirements. The source publication date is separate from this article’s publication date.
For a correction, contact PharmaEdges with the article URL and supporting source. Read our news publishing policy.
Related fda intelligence
- FDA publishes final ICH E2B(R3) guidance for electronic safety reports
- FDA proposes updated principles for container closure quality
- FDA issues inspection programme for CDER-regulated biologics
- FDA proposes guidance on responding to Form 483 observations